CONCORD, ONTARIO–(Marketwire – Aug. 20, 2010) – Futuremed Healthcare Income Fund (TSX:FMD.UN) today announced the monthly cash distribution for August 2010 has been set at $0.0771 per unit, or $0.925 per unit on an annualized basis.

The distribution will be paid on September 15^th, 2010, to unit holders of record as at August 31^st, 2010.

Futuremed is Canada’s leading value-added distributor of consumable nursing home supplies and specialized furniture and equipment to the growing long-term care facilities sector.

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

ALEXANDRIA, VA–(Marketwire – August 20, 2010) – All people with type 1 diabetes, and some with type 2, need to inject or pump insulin into their bodies to survive. Figuring out how much insulin is necessary requires frequent monitoring and can be difficult, even risky. According to Diabetes Forecast, the consumer magazine of the American Diabetes Association, one of the most hopeful trends in diabetes research is the quest to develop an artificial pancreas, a device that could make the lives of people with diabetes safer, healthier and easier — possibly within the next few years.

Despite its name, the artificial pancreas would not replace the entire biological organ. Instead, its goal is to mimic the pancreatic beta cells, which are destroyed by a malfunctioning immune system in type 1 diabetes or have stopped producing adequate insulin supply in type 2 diabetes. The artificial pancreas would consist of three components; the first two, an insulin pump and a continuous glucose monitor (CGM), are already used by many people with diabetes. It’s the third piece that acts like a glue between the two systems: an algorithm that will turn data from the CGM into instructions for the insulin pump. “Closing the loop” with an algorithm may allow for an automated system of insulin dosing, allowing the person wearing the device to spend less time on daily diabetes management.

So if we already have insulin pumps and CGMs and we can do some math, why isn’t the artificial pancreas already in place? The main reason is the math itself — and its ability to contribute to safety. While some versions of the algorithm are being developed based on decades of diabetes research and even account for the imperfections of mechanical systems, like delays in CGM measurements or insulin delivery, the line between the ideal blood glucose range and a dangerously low level is very narrow. In fact, Aaron Kowalski, PhD, who oversees the Artificial Pancreas Project at the Juvenile Diabetes Research Foundation, tells Diabetes Forecast that the ideal target for glucose levels is “right next to hypoglycemia, so there’s very little buffer.”

As the artificial pancreas concept evolves, it has taken research into new directions, including shut-off mechanisms for insulin pumps when glucose levels drop too low, pumps that deliver a second hormone in addition to insulin that would raise blood glucose, faster-acting insulins that could make the automated artificial pancreas work more effectively, and, of course, several different algorithms with different capabilities based on an individual’s routine. Getting an artificial pancreas approved for market in the United States is going to take a lot of research — but scientists are closer than they’ve ever been before. 

The artificial pancreas would not be a cure for diabetes. But it has tremendous potential to improve and save lives. And, perhaps, the best part? “An artificial pancreas is there all the time,” says Boris Kovatchev, PhD, who developed one of the algorithms for a U.S. study. “It can make decisions while a person sleeps.” In a not too distant future, people with diabetes may finally be able to rest easy.

The September issue of Diabetes Forecast also reports on how health care reform will affect people with diabetes and their families, including what to expect, and when. By the time the new law has fully taken effect, diabetes should no longer keep people from getting and keeping adequate health insurance coverage.

This issue also offers:

• Eyes on the Prize: Prevention is crucial in combating retinopathy
• Diabetes and Dementia: Does type 2 care also bolster brain function?
• Pump Up the Volume: How to eat more but lose weight

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

ALEXANDRIA, VA–(Marketwire – August 20, 2010) – All people with type 1 diabetes, and some with type 2, need to inject or pump insulin into their bodies to survive. Figuring out how much insulin is necessary requires frequent monitoring and can be difficult, even risky. According to Diabetes Forecast, the consumer magazine of the American Diabetes Association, one of the most hopeful trends in diabetes research is the quest to develop an artificial pancreas, a device that could make the lives of people with diabetes safer, healthier and easier — possibly within the next few years.

Despite its name, the artificial pancreas would not replace the entire biological organ. Instead, its goal is to mimic the pancreatic beta cells, which are destroyed by a malfunctioning immune system in type 1 diabetes or have stopped producing adequate insulin supply in type 2 diabetes. The artificial pancreas would consist of three components; the first two, an insulin pump and a continuous glucose monitor (CGM), are already used by many people with diabetes. It’s the third piece that acts like a glue between the two systems: an algorithm that will turn data from the CGM into instructions for the insulin pump. “Closing the loop” with an algorithm may allow for an automated system of insulin dosing, allowing the person wearing the device to spend less time on daily diabetes management.

So if we already have insulin pumps and CGMs and we can do some math, why isn’t the artificial pancreas already in place? The main reason is the math itself — and its ability to contribute to safety. While some versions of the algorithm are being developed based on decades of diabetes research and even account for the imperfections of mechanical systems, like delays in CGM measurements or insulin delivery, the line between the ideal blood glucose range and a dangerously low level is very narrow. In fact, Aaron Kowalski, PhD, who oversees the Artificial Pancreas Project at the Juvenile Diabetes Research Foundation, tells Diabetes Forecast that the ideal target for glucose levels is “right next to hypoglycemia, so there’s very little buffer.”

As the artificial pancreas concept evolves, it has taken research into new directions, including shut-off mechanisms for insulin pumps when glucose levels drop too low, pumps that deliver a second hormone in addition to insulin that would raise blood glucose, faster-acting insulins that could make the automated artificial pancreas work more effectively, and, of course, several different algorithms with different capabilities based on an individual’s routine. Getting an artificial pancreas approved for market in the United States is going to take a lot of research — but scientists are closer than they’ve ever been before. 

The artificial pancreas would not be a cure for diabetes. But it has tremendous potential to improve and save lives. And, perhaps, the best part? “An artificial pancreas is there all the time,” says Boris Kovatchev, PhD, who developed one of the algorithms for a U.S. study. “It can make decisions while a person sleeps.” In a not too distant future, people with diabetes may finally be able to rest easy.

The September issue of Diabetes Forecast also reports on how health care reform will affect people with diabetes and their families, including what to expect, and when. By the time the new law has fully taken effect, diabetes should no longer keep people from getting and keeping adequate health insurance coverage.

This issue also offers:

• Eyes on the Prize: Prevention is crucial in combating retinopathy
• Diabetes and Dementia: Does type 2 care also bolster brain function?
• Pump Up the Volume: How to eat more but lose weight

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

NEW YORK, NY–(Marketwire – August 20, 2010) –  The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.

Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment. 

While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:

• minimal invasiveness,
• rapid imaging processing time,
• low imaging cost,
• low radiation dose, and
• optimal resolution and contrast.

“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”

The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.

Kalorama Information’s report, “Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging),” contains more information on market forecasts, company profiles, and trends in the molecular imaging market. The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79480&productid=2613825.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

NEW YORK, NY–(Marketwire – August 20, 2010) –  The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.

Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment. 

While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:

• minimal invasiveness,
• rapid imaging processing time,
• low imaging cost,
• low radiation dose, and
• optimal resolution and contrast.

“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”

The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.

Kalorama Information’s report, “Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging),” contains more information on market forecasts, company profiles, and trends in the molecular imaging market. The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79480&productid=2613825.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

CLIFTON, NJ–(Marketwire – August 20, 2010) – Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a global leader in perimeter security systems, today announced receipt of orders totaling $1.1 million for security upgrades at several U.S. Air Force bases and nuclear power stations to meet updated force protection and NRC requirements. In addition, proposals have been submitted for other U.S. Air Force base and nuclear power station upgrades scheduled for fiscal 2011 and 2012.

“These security upgrades have been in the planning stage since 2008 following the terror attacks against our domestic assets in 2001. All branches of government including the nuclear facilities are upgrading and hardening our facilities at an accelerated pace. The NRC has always been one step ahead of potential terrorist threats, and the Department of Defense has increased its efforts in hardening its facilities as well,” commented Arthur Barchenko, President and CEO of ECSI. “Our business is about assisting in the development of security solutions to prevent infiltration of high-value assets and to guard against potential terrorist penetration. We are very proud to be part of this on-going security and anti-terrorism process to help protect the nation’s sensitive and high-visibility sites.” 

These security upgrades include the design and installation of multi-layer security systems including ECSI’s Infrared Perimeter Intrusion Detection (IPID®) system, Fiber Optic Intelligence Detection System (FOIDS®), Intelligent Video Motion Detection (IVMD®) and infrared pan-tilt-zoom camera technology.

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high-profile, high-threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, receipt and timing of collections from purchase orders, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

CLIFTON, NJ–(Marketwire – August 20, 2010) – Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a global leader in perimeter security systems, today announced receipt of orders totaling $1.1 million for security upgrades at several U.S. Air Force bases and nuclear power stations to meet updated force protection and NRC requirements. In addition, proposals have been submitted for other U.S. Air Force base and nuclear power station upgrades scheduled for fiscal 2011 and 2012.

“These security upgrades have been in the planning stage since 2008 following the terror attacks against our domestic assets in 2001. All branches of government including the nuclear facilities are upgrading and hardening our facilities at an accelerated pace. The NRC has always been one step ahead of potential terrorist threats, and the Department of Defense has increased its efforts in hardening its facilities as well,” commented Arthur Barchenko, President and CEO of ECSI. “Our business is about assisting in the development of security solutions to prevent infiltration of high-value assets and to guard against potential terrorist penetration. We are very proud to be part of this on-going security and anti-terrorism process to help protect the nation’s sensitive and high-visibility sites.” 

These security upgrades include the design and installation of multi-layer security systems including ECSI’s Infrared Perimeter Intrusion Detection (IPID®) system, Fiber Optic Intelligence Detection System (FOIDS®), Intelligent Video Motion Detection (IVMD®) and infrared pan-tilt-zoom camera technology.

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high-profile, high-threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, receipt and timing of collections from purchase orders, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 20, 2010) – www.wallstreetequityresearch.com gives shareholders valuable insight on REIT – healthcare facilities stocks Nationwide Health Properties Inc. (NYSE: NHP) and HCP Inc. (NYSE: HCP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Investors in the REIT healthcare facility sector are hoping that an aging population of baby boomers and recent healthcare reform will translate to solid bottom lines for companies in the sector. Recent increases in occupancy at senior care facilities are reflective of a population drifting into old age.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports REIT – healthcare facilities industry; traders looking for analyst opinions on Nationwide Health Properties Inc., HCP Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

While interest expenses have put a damper on some companies’ earnings, the sector remains positive about the future as the population continues to age and the number of senior care facilities remains comparatively low. Companies are looking to partnerships and mergers to acquire more real estate, including medical office buildings and nursing care projects.

The increased buying activity, especially in medical office buildings, is due in part to the security of the investment. Generally speaking, medical office buildings provide positive returns over long periods of time. This coupled with the potential influx of customers has made medical office buildings attractive to many REIT healthcare companies. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the REIT – healthcare facilities industry in today’s economic environment.

Early this month, Nationwide Health Properties Inc. posted its financial results with revenue surging 13% whilst HCP Inc. saw its revenue increase to $303 million. Traders can have complimentary access to today’s complete research reports on HCP Inc. and Nationwide Health Properties Inc. by signing up at http://wallstreetequityresearch.com/August202010HCPInc.(HCP)200810.php or http://wallstreetequityresearch.com/August202010NationwideHealthPropertiesInc.(NHP)200810.php. 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 20, 2010) – www.wallstreetequityresearch.com gives shareholders valuable insight on REIT – healthcare facilities stocks Nationwide Health Properties Inc. (NYSE: NHP) and HCP Inc. (NYSE: HCP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Investors in the REIT healthcare facility sector are hoping that an aging population of baby boomers and recent healthcare reform will translate to solid bottom lines for companies in the sector. Recent increases in occupancy at senior care facilities are reflective of a population drifting into old age.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports REIT – healthcare facilities industry; traders looking for analyst opinions on Nationwide Health Properties Inc., HCP Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

While interest expenses have put a damper on some companies’ earnings, the sector remains positive about the future as the population continues to age and the number of senior care facilities remains comparatively low. Companies are looking to partnerships and mergers to acquire more real estate, including medical office buildings and nursing care projects.

The increased buying activity, especially in medical office buildings, is due in part to the security of the investment. Generally speaking, medical office buildings provide positive returns over long periods of time. This coupled with the potential influx of customers has made medical office buildings attractive to many REIT healthcare companies. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the REIT – healthcare facilities industry in today’s economic environment.

Early this month, Nationwide Health Properties Inc. posted its financial results with revenue surging 13% whilst HCP Inc. saw its revenue increase to $303 million. Traders can have complimentary access to today’s complete research reports on HCP Inc. and Nationwide Health Properties Inc. by signing up at http://wallstreetequityresearch.com/August202010HCPInc.(HCP)200810.php or http://wallstreetequityresearch.com/August202010NationwideHealthPropertiesInc.(NHP)200810.php. 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

SUN VALLEY, CA–(Marketwire – August 20, 2010) –  XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, received confirmation that the Delaware Chancery Court has scheduled a mediation of the lawsuit that XTend commenced against U&I Bio-Tech Korea, U&I Bio-Tech California, Mr. Sam Lee, and Mr. Eric Shin. Through the litigation, XTend seeks to compel the defendants to perform their obligations under an Asset Purchase Agreement that the parties signed last December, including assigning all of the intellectual property associated with the BioHarp technology to XTend. The mediation proceeding is scheduled for September 30, 2010 at 9:30 am ET before the Honorable Sam Glasscock, III, Master in Chancery.

Mr. Paul D. Lisenby, the CEO of XTend, stated, “XTend Medical has secured a date from the Delaware Chancery Court for mediation between XTend and Sam Lee and the other defendants. It is our intention to present the facts of this case to Master Glasscock and to rely on his wisdom and expertise in complex business matters to assist the parties in resolving the case. The delays and disruption that the defendants have imposed on the company and its shareholders will hopefully finally come to an end through the mediation process. XTend feels very confident in the merits of its case against the defendants. Nevertheless, we look forward to putting this dispute behind us and moving forward with the development of the BioHarp.”

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. For further information, please contact the company at [email protected] or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

SUN VALLEY, CA–(Marketwire – August 20, 2010) –  XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, received confirmation that the Delaware Chancery Court has scheduled a mediation of the lawsuit that XTend commenced against U&I Bio-Tech Korea, U&I Bio-Tech California, Mr. Sam Lee, and Mr. Eric Shin. Through the litigation, XTend seeks to compel the defendants to perform their obligations under an Asset Purchase Agreement that the parties signed last December, including assigning all of the intellectual property associated with the BioHarp technology to XTend. The mediation proceeding is scheduled for September 30, 2010 at 9:30 am ET before the Honorable Sam Glasscock, III, Master in Chancery.

Mr. Paul D. Lisenby, the CEO of XTend, stated, “XTend Medical has secured a date from the Delaware Chancery Court for mediation between XTend and Sam Lee and the other defendants. It is our intention to present the facts of this case to Master Glasscock and to rely on his wisdom and expertise in complex business matters to assist the parties in resolving the case. The delays and disruption that the defendants have imposed on the company and its shareholders will hopefully finally come to an end through the mediation process. XTend feels very confident in the merits of its case against the defendants. Nevertheless, we look forward to putting this dispute behind us and moving forward with the development of the BioHarp.”

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. For further information, please contact the company at [email protected] or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

FORT LAUDERDALE, FL–(Marketwire – August 20, 2010) –  For 13 years, God’s Little Acres (GLA), a non-profit organization, has provided free recreational opportunities for terminally ill and developmentally disabled children. Surviving solely on donations and volunteer support, GLA faces the prospect of shutting down its five-acre ranch in Coconut Creek, FL.

Two weeks ago, GLA was issued a notice from the Bank of America stating foreclosure proceedings against their mortgage were in process.

“I wondered what on earth are we going to do,” Joan Nast, GLA co-founder said. “We have events scheduled and children to help — not to mention eight horses, one Emu and a flock of trained chickens to find a new home for.”

Like many other organizations, GLA’s financial hardships began when GLA’s other co-founder, Bob Nast, could no longer find work as a general contractor. Along with Bob, regular donors and financial backers of GLA were also affected by economic conditions. Without donations, GLA found itself unable to pay the mortgage on their property.

GLA turned to American Residential Law Group (ARLG), a law firm specializing in loan modification assistance and service, to help them regain control on their financial situation. ARLG sent senior attorney, Joel Jacobi, to plead GLA’s case. After demonstrating the humanitarian efforts undertaken by GLA over the years, the judge granted GLA another six months to complete their loan modification.

“[ARLG] is a wonderful firm; honest and rooted in integrity and extreme efficiency,” Joan said. “We aren’t the norm in terms of companies that ask for and are granted home loan modifications, and ARLG has understood that from the beginning.”

This extension will enable GLA to finish their loan modification and keep the ranch activities available for the children and their families. Even though this recent development is good news for GLA, they are still in need of donations and grant money. Joan hopes that one day she will be able to build an indoor facility to accommodate the children who are sensitive to outdoor conditions, but in the mean time, she is focusing on saving the ranch.

“They [ARLG] have used every resource available to help us keep our charity running and we are grateful,” Joan said. “God will send us [financial] backers to get this mortgage paid off.”

If you are interested in donating to God’s Little Acres, please visit their website at www.godslittleacres.org.

About God’s Little Acres: God’s Little Acres is a 501(c)(3) non-profit, multi-cultural, non-religious Florida licensed charity that provides safe and controlled recreational opportunities for terminally ill and developmentally disabled children between the ages of 2 and 11 with their families. The five-acre ranch is located in Coconut Creek, Florida; it serves as an escape for seriously ill children from their typical hospital surroundings. The childrens’ diagnosis include cancer, leukemia, AIDS, cerebral palsy, autism, down syndrome, multiple sclerosis, muscular dystrophy, cystic fibrosis and many other afflictions. 

About American Residential Law Group: American Residential Law Group is a law firm that strives to provide the community with legal assistance and all the benefits to which consumers are entitled under the law. With a considerable background in all areas of consumer advocacy, American Residential Law Group remains dedicated to providing integrity and excellence for their clients and increasing their quality of life. To learn more about home mortgage modifications and how American Residential Law Group can be of assistance to you, visit them at http://www.ARLGNow.com.

GOLDEN VALLEY, MN–(Marketwire – August 19, 2010) –  Health Fair 11 at the Fair celebrates its tenth year of providing free or low-cost health screenings to people attending the Minnesota State Fair. 

During the past decade, fairgoers have flocked to the Health Fair 11 building to take advantage of great health-related offerings for people of all ages. Since 2001, 370,000 health screenings have been documented at Health Fair 11 at the Fair.

This year, Health Fair 11 building visitors will find blood pressure checks, diabetes screenings, bone density and body mass measurements, hearing and vision assessments, blood typing, balance evaluations, and free tote bags in which to carry health and wellness information materials they obtain from exhibitors. Fairgoers can step on the official weight scale, pick up information on food allergies and celiac disease, and have their children tested for lead exposure. 

New this year: Germ City and Great Hang Up
How clean are your hands? Does your child do a good job of washing his or her hands? Families can learn if they have good hand washing skills by taking a trip through the Minnesota Department of Health’s Germ City. The exhibit includes “glitterbug goo,” black light booths, and hand washing sinks.

Fairgoers will also have the opportunity to take KARE 11’s Great Hang Up pledge. The pledge is a public health campaign to convince people to not talk or text on a cell phone or other mobile device while driving. Health Fair 11 has created special “DRIVE NOW-Talk/TXT L8R” window clings to encourage people to take the pledge and then share the message. Clings will be available daily from 6 – 9 p.m.

Get a flu shot before school starts
Flu shots will be available daily from 9 a.m. to 6 p.m. Nurses with the nonprofit Minnesota Visiting Nurse Agency (MVNA) will vaccinate people ages three and older. Minors must be accompanied by a parent or guardian. Both the injectable vaccine and nasal spray vaccine will be available. The MVNA encourages people to bring proof-of-insurance cards. Parents: this is a perfect time to have your children vaccinated before they get exposed to the flu virus at school.

Location, location, location
Health Fair 11 at the Fair is located on the southwest corner of Dan Patch Ave. and Cooper St. The building is open daily from 9 a.m. to 9 p.m. The exhibit is made possible by Health Fair 11, a partnership of KARE TV, UCare, and North Memorial Medical Center. 

BOCA RATON, FL–(Marketwire – August 19, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Drs. Daniel Weiss and Jerry Anchin, Vicor’s Chief Medical Officer and Director of Research and Development, respectively, participated in the start of a new cardiac screening initiative being conducted by Cardiac Risk in the Young (CRY), a London-based non-profit organization. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Specifically, Drs. Weiss and Anchin trained technicians in the use of the Company’s PD2i^® nonlinear algorithm and supervised initial data collection efforts. Approximately 30 14 year olds were tested with the PD2i^® nonlinear algorithm. The multi-year CRY initiative will offer free cardiac screening to 14 year olds (DOB 1995); 14 is the earliest post-puberty age for which proactive screening is considered valuable. Participants will then be tested annually through age 19. In addition to identifying those youngsters who are at elevated risk of sudden cardiac death for referral for further evaluation, a goal of the study is to assess the changes that occur in those risk factors through the teenage years. Approximately 600 young people are struck down by sudden cardiac death annually in the U.K. Ten percent of the estimated seven million individuals fitting this description are expected to participate.

Dr. Sanjay Sharma, the consulting cardiologist spearheading the initiative, selected Vicor’s PD2i^® nonlinear algorithm for use in the CRY screening initiative. The ultimate goal of the screening initiative is to improve the accuracy of identifying teenagers at elevated risk of sudden cardiac death in the future.

“We’re delighted by the level of enthusiasm the CRY staff showed for the PD2i^®. Initially, the technicians were hesitant about including the PD2i^® test in their screening regimen because they were unfamiliar with it. Once they discovered how easy to use it is — by lunch time of the first day — they were very excited to be using the PD2i^®, a tool that, they said, adds tremendous value to their efforts by enabling a risk prognostic. The CRY screening initiative is an incredibly well-organized and professionally-run operation. No doubt it will be a great success in furthering understanding of cardiac death in the young,” stated Dr. Anchin.

The CRY screening initiative takes place two weekends per month at the Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George’s Healthcare NHS Trust. Azra Loncarevic-Srmic, project manager, oversees three ECG technicians, an echocardiogram technician, a resident cardiologist, and two schedulers. According to Ms. Loncarevic-Srmic, they anticipate screening 300 participants per weekend.

“We’re honored to have our PD2i^® nonlinear algorithm selected for use in this important initiative. Given the consistently accurate results achieved, to date, with the PD2i^® nonlinear algorithm in risk stratifying adults at risk of sudden cardiac death, we’re confident that the PD2i^® nonlinear algorithm will prove beneficial in identifying youths in need of treatment to prevent a cardiac episode,” stated Mr. Fater.

Dr. Sharma is Professor of the recently-created Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George’s Healthcare NHS Trust. The Inherited Cardiovascular Disease and Sports Cardiology Centre is the world’s first specialist, multi-disciplinary facility dedicated to providing services to populations — those between the ages of 14 and 35, including families and athletes — affected by or at risk for sudden cardiac death. St. George’s is one of England’s largest teaching hospitals and the first hospital in the United Kingdom to develop a specialist clinic for young sudden cardiac death after receiving CRY’s donation of echocardiogram equipment. CRY was founded in 1996 to raise awareness of conditions that can lead to sudden cardiac death and sudden cardiac death syndrome in those between the ages of 14 and 35. Additional information about CRY may be found at http://www.c-r-y.org.uk/.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Institute for Surgical Research, the Department of the Army, Department of Defense, the U.S. Government, or CRY of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-13

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – August 19, 2010) – Metiscan, Inc. (PINKSHEETS: MTIZ) is pleased to announce that the Company will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. The Company will be discussing its recent operational accomplishments that have transpired over the previous six months as well as providing insight into objectives Metiscan has outlined for the near term.

The nationwide teleconference will be hosted and moderated by Marc Jablon, CEO of Big Apple Consulting USA. The featured speakers for Metiscan will be Bryan Scott, President, CEO & Director, Janine Frieh, CFO & Director, and Brian Hart, COO & Director.

Space is limited on the call-in lines for this national teleconference, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for Mr. Scott, Ms. Frieh or Mr. Hart, please email questions in advance to [email protected].

“This venue is a great platform for us to share information with our shareholders and discuss Metiscan’s story,” stated Bryan A. Scott, CEO & President of Metiscan, Inc.

About Metiscan, Inc.

Metiscan, Inc. (Metiscan), OTCPK: MTIZ, is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. 

Click here to see all recent news from this company